Monday, August 31, 2026

Moderna Stock Is 17.73% Up So Far On Friday

ViaNews Editorial Team

November 27, 2020

Moderna Stock Is 17.73% Up So Far On Friday

Shares of Moderna jumped by a staggering 17.73% to $128.54 at 11:07 EST on Friday, following yesterday's upward trend. The Nasdaq Stock Market is jumping 1.07% to $12,224.10, after three successive sessions in a row of gains, on what so far seems, an all-around positive trend trading session today.

Moderna's last close was $109.18, 3.71% under its 52-week high of $123.94.

Moderna's sales growth is 1425.2% for the present quarter and 9666.5% for the next. The company's growth estimates for the present quarter is a negative 48.6% and positive 437.1% for the next.

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's stock is valued at $128.54 at 11:07 EST, higher than its 52-week high of $123.94.

Moderna's worth is way above its 50-day moving average of $79.01 and way higher than its 200-day moving average of $70.45.

According to Bloomberg Quint on Mon Nov 23, "Moderna Chief Sells More Shares Ahead of Urgent Vaccine Filing."

According to Bloomberg Quint on Wed Nov 25, "Moderna Soars to Record Ahead of Final Covid Vaccine Analysis."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com